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ABSTRACT 
 
Objective: The purpose of this study was to estimate the frequency of ovarian metastasis in patients of endometrial 
cancer, to examine the clinico- pathological characteristics of cases with ovarian metastasis and to identify 
associated predictive factors in endometrial adenocarcinoma. Materials and Methods: We reviewed the clinical 
and pathological records of endometrial carcinoma cases diagnosed and treated at our institute between 2007 and 
2015. Patient who received primary surgical treatment form the basis of this study. The histopathology reports were 
studied for information on the following: histology type, grades, depth of myometrial invasion, cervical involvement 
and lymph node status. Information regarding patient’s age was extracted from medical records. These data were 
then analyzed and compared for relation of ovarian metastasis with various risk factors. Results: Total 372 cases of 
endometrial carcinoma were evaluated. Out of these 32(8.6%) patients had ovarian metastases. No patient under the 
age of 40 years had ovarian metastasis. 13.3% of patients with more than 50% myometrial invasion and 39.2% of 
patients with cervix stromal involvement showed ovarian metastasis. There was no ovarian involvement with well 
differentiated adenocarcinoma as compare to 12.8% with poorly differentiated carcinoma and 38.9% with Non 
Endometrioid adenocarcinoma. Conclusion: The risk of ovarian metastasis in patients without predictable risk 
factors is minimal. Therefore, it may be possible to preserve ovaries in young women with low grade endometrial 
carcinoma confined to uterus. However further prospective studies are needed before current recommendation can 
be changed. 
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Introduction
Endometrial carcinoma is the most common 
malignancy of the female genital tract in the western 
world and the fourth most common malignancy in 
women after breast, lung and colorectal cancer. 
Developing countries and Japan have incidence rates 
four to five times lower than Western industrialized  
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nations with lowest rates being in India and south Asia 
[1, 2].Most cases (75–85%) of endometrial carcinoma 
occur between the fifth and seventh decades of life, and 
95% occur in patients over 40 years of age. 
Approximately 20% of patients, however, are 
diagnosed before menopause, and 5% are diagnosed 
before the age of 40 years. In the present study 7.79% 
of cases were below the age of 40 years [3]. 
Endometrial cancer staging is based on surgery. 
Standard treatment consists of a total abdominal 
hysterectomy and bilateral salpingo–oophorectomy 
(BSO), often accompanied by lymphadenectomy. 
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Current recommendation is to remove the ovaries in all 
cases of endometrial carcinoma regardless of age; The 
rationale being the ‘high’ rate of ovarian metastasis, 
possibility of a coexisting synchronous primary ovarian 
tumor and possible contribution made by ovarian 
hormones on microscopic foci of residual endometrial 
cancer [1, 3].The impact of premature menopause on 
the quality of life, cardiovascular and bone systems 
should not be neglected in young patients. Thus, 
gynecological oncologists face a difficult choice in the 
management of young patients with endometrial 
cancer. A few reports from United States and Korea 
have demonstrated similar survival rates with ovarian 
preservation in young women with endometrial cancer. 
However the issue is highly controversial and requires 
further studies before recommendation for 
oophrectomy can be changed [4].The purpose of this 
study was to estimate the frequency of ovarian 
metastasis in patients of endometrial cancer, to 
examine the clinico- pathological characteristics of 
cases with ovarian metastasis and to identify associated 
predictive factors in endometrial cancer.   
 
Materials & Method 
 
 In a retrospective study, we reviewed the clinical and 
pathological records of endometrial carcinoma cases 
diagnosed and treated at our institute between 2007 and 
2015. Patient who received primary surgical treatment 
form the basis of this study. Patients who received 
chemotherapy or radiotherapy as initial treatment were 
excluded from our study. Also excluded were patients 
in which complete data was unavailable. Patients with 
component of mixed mullerian tumor, carcinosarcoma, 
or endodermal stromal sarcoma were excluded. 
Inoperable cases, patients with synchronous primary 
ovarian malignancy and patients of breast malignancy 
who later developed carcinoma endometrium, were 
also not included in the study.The majority of patients 
included had total abdominal hysterectomy, bilateral 
salpingoophrectomy, bilateral pelvic lymphadenectomy 
and omental sampling or omentectomy for endometrial 
carcinoma at our institute. A few patients, who had 
undergone incomplete surgical treatment (only 
hysterectomy) elsewhere and then underwent restaging 
surgery at our institute, were also included in our study, 
if the original report was available for review. Totally 
372 patients of carcinoma of endometrium were 
included in our study.  The original histopathology 
reports were studied for information on the following 
prognostic factors:  histologic type, grade, depth of 
myometrial invasion, cervical involvement and lymph 
node status. Information regarding patient’s age was 
extracted from medical records. These data were than 
analyzed and compared for rate of ovarian metastasis 
and also to evaluate associated prognostic factors to 
predict ovarian metastasis in endometrial carcinoma. 
The obtained data were compared in Chi-square tests. 
Probability value less than 0.05 were considered as 
statistically significant. For statistical purpose 
endometrioid tumors, endometrioid tumor with 
squamous differentiation and villoglandular type were 
all grouped together as Endometrioid adenocarcinoma. 
Only Endometrioid adenocarcinoma types were further 
graded as well, moderate and poorly differentiated 
carcinoma. In present study 21cases had Non 
Endometrioid histology of which 16 had uterine 
papillary serous carcinoma (UPSC) and 5 had clear 
cell. As both of these are very aggressive histology, 
grading was not applicable.  
 
Results 
We analyzed 372 cases of endometrial cancer in the 
study. Table 1 show that a significant number of 
women with endometrial carcinoma (7.79%) were 
under 40 years of age. Thirty two patients (8.6%) were 
identified to have ovarian metastases. 7.4% of cases 
above the 60years and 11.5% cases between 50-60 
years had ovarian metastasis. No patient under the age 
of 40 years had ovarian metastasis (Table-2).  Out of 
372 patients, 351(94.3%) had Endometrioid type, while 
21(5.6%) had Non Endometrioid type of 
adenocarcinoma.  Among the Endometrioid group 342 
had endometrioid adenocarcinoma, 6 had 
adenosquamous carcinoma and 3 had villoglandular 
carcinoma. Non Endometrioid type included 16 cases 
of uterine papillary serous carcinoma (UPSC) and 5 
cases of clear cell carcinoma (Table-3).  Twenty nine 
out of 351cases with Endometrioid type were ≤ 
40years, while no patients of Non Endometrioid were ≤ 
40years; i.e. all the patients under the age of 40 years 
had Endometrioid adenocarcinoma.  52.3 %( 11/21) of 
Non Endometrioid type were seen in patient’s above 
60. Among the Endometrioid adenocarcinoma 
patient’s, grade was compared with age. In patient ≤ 40 
years, 68.9 %( 20/29) had well differentiated 
adenocarcinoma and none had poorly differentiated 
adenocarcinoma. 48.7% (38/78) of poorly 
differentiated adenocarcinoma were seen in patients 
above 60(Table-4). Ovarian metastases were seen in 
6.8% (24/351) of Endometrioid adenocarcinoma, and 
38.9% in Non Endometrioid Adenocarcinoma (Table-
5).  Statistical analysis of ovarian metastasis in Non-
Endometrioid Adenocarcinoma shows p-value of 
0.00005, which was statistically significant. Among the 
Endometrioid adenocarcinoma cases the incidence of 
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ovarian metastasis was 0%, 11.4% and 12.8% in well, 
moderately and poorly differentiated adenocarcinoma 
respectively (Table-6).  Absence of ovarian metastasis 
in 151 cases of well differentiated Endometrioid 
adenocarcinoma is statistically significant (p-value: 
0.00056).Ovarian metastasis were seen in 13.3% of the 
patient with more than 50% of myometrial invasion (p-
value: 0.003) as against only 4.1% of the patient with 
less than 50% myometrial invasion (Table-7).Ovarian 
metastases were seen in 6.07% of patients without any 
cervical involvement and another 6.4% with only 
cervical epithelial involvement. However 39.2% of 
patients with cervix stromal involvement showed 
ovarian metastasis, p-value: 0.000002(Table-8).  Of 32 
patients with ovarian metastases, 6 patients also had 
lymph node metastases. 
Results: 
Table 1:  Distribution of cases of endometrial carcinoma according to age 
 
      Age Number of cases  
≤40 years     29     (7.79%) 
41 -50years      92     (24.7%) 
51 – 60 years    130      (34.9%) 
>60years    121      (32.5%) 
Total cases   372 
 
 
Table 2: Relationship of age with ovarian metastasis 
 
Age Total cases Cases with ovarian metastasis 
≤40 yrs 29                            0      (0%) 
41-50yrs 92 8     (8.6%) 
51-60yrs 130 15     (11.5%) 
>60yrs 121 9     (7.4%) 
Total 372 32     (8.60%) 
 
 
Table 3: Distribution of cases according to histopathological types 
 
      Total cases 372 
1.   Endometrioid adenocarcinoma 351   (94.3%) 
• endometrioid adeno carcinoma  342    
• Adenosquamous carcinoma      6       
• Villoglandular carcinoma               3      
      2.   Non Endometrioid adenocarcinoma            21   (5.6%) 
•  Uterine  papillary serous carcinoma             16     
•  Clear cell carcinoma              5       
 
Table 4:  Relationship of histology type with age of the patient 
 
Total Age 
≤40 years 40-50  50-60  60 above 
Endometrioid adenocarcinoma*n=351 29 90 122 110 
• Well Differentiated n=151 20 48 48 35 
• Moderately Differentiated n=122 9 24 52 37 
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• Poorly Differentiated n=78 0 18 22 38 
Non Endometrioid adenocarcinoma n=21 0 2 8 11 
* Grading is done only for Endometrioid adenocarcinoma 
Table 5: Relationship of histological types with ovarian metastasis 
 
   Histopathological types Total cases  Cases with ovarian metastasis 
1. Endometrioid Adenocarcinoma      351       24     (6.8%) 
    2.    Non-Endometrioid Adenocarcinoma        21         8     (38.9%) 
 
 
Table 6: Relationship of grade of Endometroid adenocarcinoma with ovarian metastasis 
 
Grade of Endometrioid adenocarcinoma No. of  total cases  Ovarian   metastasis 
• Well Differentiated 151              0   (0%) 
• Moderately Differentiated 122            14    (11.4%) 
• Poorly Differentiated 78             10    (12.8%) 
                    Total 351             24 
 
Table 7: Relationship of depth of myometrial invasion with ovarian metastasis 
  
Depth of myometrial invasion Total cases Cases with ovarian metastasis 
<1/2    192      8   (4.1%) 
≥1/2    180    24   (13.3%) 
 
Table 8:  Relationship of cervical involvement with ovarian metastasis 
 
Types of Cervical involvment Total cases Cases with ovarian metastasis 
No cervical Involvement     313     19   (6.07%) 
Cervical epithelium       31       2   (6.4%) 
Cervical  stromal       28     11   (39.2%) 
 
Thirty five patients out of 372 had lymph node metastasis. Of these 6 occurred in patient who had ovarian 
metastasis. 
Discussion 
Surgery is the cornerstone of treatment for endometrial 
carcinoma. Bilateral salpingo-oophrectomy(BSO) 
regardless of age is currently recommended along with 
hysterectomy and staging procedure. This treatment 
policy has not been changed since 1988. The rationale for 
this is based on the theoretic risks of preserving the 
ovaries: ‘high’ rate of ovarian metastasis, the possibility 
of a coexisting synchronous primary tumor within the 
ovaries and the possible contribution made by ovarian 
hormones on pathogenesis of endometrial cancer. 
However a significant population of women suffering 
from carcinoma endometrium is premenopausal and about 
5% is below the age of 40 years [5]. BSO places them at 
risk of long term estrogen deprivation. Many trials are 
being carried out to evaluate the safety of ovarian 
preservation in young women with endometrial cancer [3, 
5].Many studies have found that young women with 
endometrial cancer have a more favorable prognosis than 
older patients. Premenopausal women often have low-
grade, early-stage tumors that may, in part explain the 
differential survival. However, there is a lack of 
information regarding the prognostic factors that predict 
the risk of ovarian involvement at the time of surgery.  
Therefore, a largely unanswered question is the safety of 
ovarian preservation in young women with endometrial 
cancer. Although prior reports have examined the risk of 
ovarian metastasis in young women with endometrial 
cancer, there are not enough data regarding safety of 
ovarian conservation [6].In our study 7.79% of the 
endometrial carcinoma patients were below the age of 40 
years. Majority of young patients (69.9%) had well 
differentiated Endometrioid adenocarcinoma. No patient 
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below the age of 40years had poorly differentiated or Non 
endometrioid adenocarcinoma (papillary or clear cell 
carcinoma). In contrast majority of poorly differentiated 
adenocarcinoma 48.7 %( 38/78), and Non endometriod 
adenocarcinoma cases (11/21) were seen in patients above 
60years. This shows that age at diagnosis is an 
independent prognostic factor. Lee et al. showed that 
women older than 40 years were less likely to have stage I 
disease and grade I tumors but more likely to have uterine 
papillary serous histology than women aged 40 years and 
younger[7] as seen in our study. Their studies also showed 
that age at diagnosis is an independent prognostic factor 
for survival.  Zaino et al. reported 5-year survival rates of 
96.3% for patients 50 years or younger [8].In the present 
study the overall rate of ovarian metastasis in endometrial 
cancer patient was 8.6%.  Although this seems to support 
the rationale for BSO, when the cases with ovarian 
metastasis were further analyzed, it was found that, no 
patients below the age of 40 years had ovarian metastasis. 
There were no ovarian metastases in well differentiated 
endometrioid adenocarcinoma.  All 32 patients with 
ovarian metastases had at least one risk factor such as 
grade, type, myometrial invasion or cervical involvement. 
While only 6.8% of patient with Endometrioid 
adenocarcinoma had ovarian metastasis, 38.9% with Non 
endomerioid adenocarcinoma had ovarian metastasis. This 
emphasizes the need for detailed and expert review of 
endometrial biopsy material, preoperatively, especially 
when planning for ovarian preservation. In the present 
study 21 cases had Non endometrioid histology of which 
16 had uterine papillary serous carcinoma (UPSC) and 5 
had clear cell. These are aggressive types of endometrial 
cancer and have poor prognosis, also confirmed in our 
study. No patient with well differentiated carcinoma had 
ovarian metastasis while 11.4% and 12.8% of moderately 
and poorly differentiated carcinoma had ovarian 
metastasis respectively. The study conducted by Modaress 
et al. had similar results with no metastasis seen in well 
differentiated cases [9].  However Lee et al showed 4.6% 
ovarian metastasis in well, 7.9% in moderately and 9.1% 
in poorly differentiated carcinoma [5, 10]. Cases with 
more than 50% myometrial invasion showed significant 
risk of ovarian metastasis, (13.3%) compare to less than 
50% myometrial invasion (4.1%). In the study by Gaurin 
et al depth of myometrial invasion was the sole factor 
predictive for adnexal involvement [11]. When grade and 
depth of invasion are evaluated separately, the depth of 
invasion appears to be a more important prognostic factor 
for ovarian metastasis than the grade of the tumor [8, 12, 
13]. Our study showed that the risk of ovarian metastasis 
was only 6.4% when only cervical epithelium is involved 
as compared to cervical stromal involvement where the 
risk was 39.2%. The new FIGO staging also includes only 
cervical stromal involvement as higher stage. Two 
mechanisms have been proposed for endometrial 
carcinoma to develop ovarian metastasis. Firstly, tumor 
cells can be implanted in ovaries by directly spreading 
through fallopian tube or uterine muscular layer. The 
second mechanism of ovarian metastasis is believed to be 
through lymphatics of uterus. In the second manner of 
metastasis, positive pelvic lymph nodes, cervical stromal 
involvement, aggressive histology and negative peritoneal 
cytology are commonly present, as seen in our case [12]. 
Lymph node metastases occurred in total 35 cases (9.4%). 
Out of 32 cases of ovarian metastases patients, six 
(18.7%) had lymph node involvement. The lymph node 
status was of importance to determine the prognosis of 
patients with ovarian metastasis. According to the study 
by Takeshima et al 5 years disease free survival rates were 
72% in patients with ovarian metastasis alone,  59.6% in 
patients with pelvic lymph node metastasis alone and 0% 
in patients having both ovarian metastasis and lymph node 
metastasis [10, 12].A Surveillance, Epidemiology and End 
Results Database (SEER) analysis by Wright et al. on the 
safety of ovarian preservation in premenopausal women 
with stage I endometrial cancer showed, that ovarian 
preservation had no effect on either cancer-specific 
survival or overall survival. They concluded that ovarian 
preservation in premenopausal women with early-stage 
disease may be safe and not associated with an increase in 
cancer-related mortality [6, 9]. Chai et al. believe that 
endometrial carcinoma in patients under 45 are 
endometrioid adenocarcinoma, related with long term 
non-allopathic estrogen stimulation, and that most are 
associated with hyperplasia of endometrium. The 
prognosis is good, especially for patients younger than 35 
[9, 14].In addition to immediate consequence of hot 
flushes and vaginal atrophy, surgical menopause in young 
women results in a number of long term sequelae, 
including an increased risk of cardiovascular disease, 
osteoporosis and cognitive dysfunction. Thus to avoid the 
short term and long term consequence of surgical 
menopause, there is a strong argument for ovarian 
preservation in young women. [5, 15]In an effort to find 
out factors predictive of ovarian involvement, we have 
examined its association with other pathological factors in 
this study. Similar to GOG results we found that incidence 
of ovarian metastasis increases with age and in presence 
of other pathological factors like cervical stromal 
involvement, deep myometrial involvement, grade 3 of 
endometrioid adenocarcinoma and aggressive histology 
[6, 13]. Thus our finding favors ovarian preservation in 
young woman with well differentiated endometroid 
adenocarcinma, minimal myometrial involvement and no 
cervical involvement. Limitations of the present study 
must be considered when interpreting results. This was a 
retrospective data analysis which raises the possibility of 
missing or incomplete data. The pathologist changed over 
a period of time, leading to the possibility of, 
interobserver variability in grades and types. The rate of 
ovarian micrometastasis may have been under evaluated 
as only one cut section was examined from normal 
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appearing ovaries rather than multiple cut sections. The 
safety of ovarian preservation, in early stage of 
endometrial carcinoma needs confirmation by large scale 
studies. Ovarian preservation in endometrial cancer 
patients should be performed cautiously with 
consideration of patient’s age and patient’s desire for 
ovarian preservation after fully informed explanation of 
potential risks. Follow up of patients who have undergone 
ovarian preservation should be extended to rule out the 
possibility of subsequent ovarian metastasis [5, 6, 10, 12 ]. 
Conclusion 
According to our study ovarian preservation may be 
offered to selected young patients who want to retain 
ovarian function, with a preoperative histological 
diagnosis of well differentiated endometrioid type, disease 
confined to uterus, myometrial invasion limited to less 
than one half of the myometrium,  no cervical 
involvement and no gross pre or intraoperative 
abnormality in ovaries. However this must be confirmed 
with large, multicentric, prospective studies. Pathologists 
must be requested to take multiple sections of normal 
appearing ovaries in endometrial carcinoma patients to 
rule out micrometastases. Ovarian preservation in 
endometrial cancer should be considered as an exception, 
and proposed as an individualized plan of care for 
patients, with strict eligibility criteria.  
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